Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 alone or in Combination with other Therapies in Subjects with Advanced Thoracic Tumors with homozygous MTAP Deletion

Principal Investigator: Dy, Grace K

(XL092-305) - A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in the First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous…

Principal Investigator: Romero, Jenny

A phase 2, randomised, multi-centre, open label trial to evaluate the safety and efficacy of
intravesical nadofaragene firadenovec alone or in combination with chemotherapy
(gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with…

Principal Investigator: Li, Qiang J

A PHASE 1, FIRST IN HUMAN, DOSE-ESCALATION STUDY OF TORL-3-600 IN PARTICIPANTS WITH ADVANCED CANCER

Principal Investigator: Fountzilas, Christos

(AREN2231) Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

Principal Investigator: Twist, Clare J

A Pilot, Single-Arm, Phase II Trial of Tamoxifen plus Pegylated Liposomal Doxorubicin in Patients with Metastatic Triple Negative Breast Cancer

Principal Investigator: Kabraji, Sheheryar K

A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1)Inhibitor Bleximenib in Participants with Acute Leukemia

Principal Investigator: Wang, Eunice S

Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory…

Principal Investigator: Wang, Eunice S

(S2414) A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT)

Principal Investigator: Fitzgerald, Bailey

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Combination of CLBR00l, an Engineered Autologous T Cell Product, and ABBV-461, an Antibody-Based Biologic, in Subjects with…

Principal Investigator: Krishnamurthy, Anuradha

( I-SPY 2) Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2

Principal Investigator: Levine, Ellis G

(AAML1831) A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Principal Investigator: Twist, Clare J

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers

Principal Investigator: Kabraji, Sheheryar K

A Phase 1 Study of ASCIMINIB in combination with dasatinib, prednisone, and blinatumomab in patients with BCR-ABL1 positive (BCR-ABL1+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML)

Principal Investigator: Wang, Eunice S

NRG-GY036: A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based…

Principal Investigator: Zsiros, Emese

A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide,…

Principal Investigator: Hillengass, Jens

A phase 1b dose optimization study of sovilnesib (an oral KIF18A inhibitor) in subjects with advanced high grade serous ovarian cancer

Principal Investigator: McLean, Karen

Life on the Go 3: A Randomized Controlled Trial of Automated, Personalized Physical Activity Intervention Using Wearable Devices to Improve Immune Function and Clinical Outcomes in Ovarian and Endometrial Cancer Patients

Principal Investigator: Zsiros, Emese

(ACNS2031) A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features

Principal Investigator: Twist, Clare J

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Principal Investigator: Thompson, J

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Principal Investigator: Fountzilas, Christos

A Phase 2 Clinical Trial of Nalirifox as Neoadjuvant Treatment for Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma

Principal Investigator: Fountzilas, Christos

An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

Principal Investigator: Niu, Alex

A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Principal Investigator: Wang, Eunice S

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors

Principal Investigator: Fountzilas, Christos